Skip to main content

Advertisement

SpringerLink
Log in

Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

To describe the case of a 9-year-old male patient with neurofibromatosis type 1 (NF1), partial empty sella (PES), transient central adrenal insufficiency (CAI) and growth hormone (GH) deficiency (GHD) treated with recombinant GH (rGH).

Methods

The diagnosis of GHD was established upon peak GH response <10 ng/mL following glucagon and clonidine stimulation tests. CAI was diagnosed when peak cortisol response was <18 μg/dL following 1 μg Synacthen test (ST) with normal ACTH levels.

Results

The diagnosis of NF1 was made at the age of 1.5 year. The patient first attended our Department at the age of 4.5 years. He presented with short stature (height: 95 cm < 3rd percentile), macrocephaly, frontal bossing, café-au-lait spots and bilateral proptosis. His growth rate (GR) initially was 5.3 cm/year. Brain/pituitary MRI showed T2-hyperintensities typical for NF1 and PES with reduced pituitary gland height (3 mm). The pituitary function tests revealed GHD. During follow-up his imaging findings remained unchanged, while his GR decelerated. He was started on rGH at the age of 8.5 years. Within the following year he grew 8.7 cm in height and could preserve a normal GR thereafter. At the age of 10.3 years, he was diagnosed with CAI (maximum cortisol response post-1 μg ST: 13.1 μg/dL). Ηe received hydrocortisone for 1 year. A repeat 1 μg ST off hydrocortisone showed normal cortisol response. During follow-up, brain MRI findings remained stable, while his pituitary demonstrated normal size and signal intensity.

Conclusion

Empty sella and hypopituitarism may occur in the context of NF1. Short stature may be associated with GHD in the absence of intrasellar masses in affected individuals. Lifelong endocrine follow-up is recommended for all NF1 patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. A.C. Hirbe, D.H. Gutmann, Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 13(8), 834–843 (2014)

    PubMed  Google Scholar 

  2. V.C. Williams, J. Lucas, M.A. Babcock, D.H. Gutmann, B. Korf, B.L. Maria, Neurofibromatosis type 1 revisited. Pediatrics 123(1), 124–133 (2009)

    PubMed  Google Scholar 

  3. B. Hegedus, T.H. Yeh, D.Y. Lee, R.J. Emnett, J. Li, D.H. Gutmann, Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum. Mol. Genet. 17(19), 2956–2966 (2008)

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Y.S. Yap, J.R. McPherson, C.K. Ong, S.G. Rozen, B.T. Teh, A.S. Lee, D.F. Callen, The NF1 gene revisited—from bench to bedside. Oncotarget 5(15), 5873–5892 (2014)

    PubMed  PubMed Central  Google Scholar 

  5. S. El-Watidy, A. Jamjoom, Z.A. Jamjoom, W. Selen, Cranio-orbital anomalies in Von Recklinghausen neurofibromatosis simulating an intraorbital space-occupying lesion. Ann. Saudi. Med. 15(4), 399–401 (1995)

    CAS  PubMed  Google Scholar 

  6. E.A. Soucy, D. van Oppen, N.L. Nejedly, F. Gao, D.H. Gutmann, A.S. Hollander, Height assessments in children with neurofibromatosis type 1. J. Child. Neurol. 28(3), 303–307 (2013)

    PubMed  Google Scholar 

  7. M. Clementi, S. Milani, I. Mammi, S. Boni, C. Monciotti, R. Tenconi, Neurofibromatosis type 1 growth charts. Am. J. Med. Genet. 87(4), 317–323 (1999)

    CAS  PubMed  Google Scholar 

  8. J. Szudek, P. Birch, J.M. Friedman, Growth in North American white children with neurofibromatosis 1 (NF1). J. Med. Genet. 37(12), 933–938 (2000)

    CAS  PubMed  PubMed Central  Google Scholar 

  9. R. Vassilopoulou-Sellin, M.J. Klein, J.K. Slopis, Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr. Neurol. 22(5), 355–358 (2000)

    CAS  PubMed  Google Scholar 

  10. S.J. Howell, P. Wilton, A. Lindberg, S.M. Shalet, Growth hormone replacement and the risk of malignancy in children with neurofibromatosis. J. Pediatr. 133(2), 201–205 (1998)

    CAS  PubMed  Google Scholar 

  11. W. Waheed, M.H. Nathan, G.B. Allen, N.M. Borden, M.A. Babi, R. Tandan, Neurofibromatosis 1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like symptoms. BMJ Case Rep. (2015). https://doi.org/10.1136/bcr-2015-210816

  12. S. Raman, A. Grimberg, S.G. Waguespack, B.S. Miller, C.A. Sklar, L.R. Meacham, B.C. Patterson, Risk of neoplasia in pediatric patients receiving growth hormone therapy–a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J. Clin. Endocrinol. Metab. 100(6), 2192–2203 (2015)

    CAS  PubMed  PubMed Central  Google Scholar 

  13. C. Bizzarri, G. Bottaro, Endocrine implications of neurofibromatosis 1 in childhood. Horm. Res. Paediatr. 83(4), 232–241 (2015)

    CAS  PubMed  Google Scholar 

  14. I. Sani, A. Albanese, Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma. Horm. Res. Paediatr. 87(3), 179–188 (2017)

    CAS  PubMed  Google Scholar 

  15. D. Carmi, M. Shohat, A. Metzker, Z. Dickerman, Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics. 103(6 Pt 1), 1257–1262 (1999)

    CAS  PubMed  Google Scholar 

  16. R. Virdis, M.E. Street, M.A. Bandello, C. Tripodi, A. Donadio, A.R. Villani, L. Cagozzi, L. Garavelli, S. Bernasconi, Growth and pubertal disorders in neurofibromatosis type 1. J. Pediatr. Endocrinol. Metab. 16(Suppl 2), 289–292 (2003)

    PubMed  Google Scholar 

  17. M.L. Iezzi, G. Varriale, L. Zagaroli, M. Greco, S. Lasorella, A. Verrotti di Pianella, Growth hormone deficit as a first clinical manifestation of early diffuse cerebral glioma in patient with neurofibromatosis. Ann. Clin. Lab. Res. 5, 1 (2017)

    Google Scholar 

  18. M.H. Cnossen, E.N. Stam, L.C. Cooiman, H.J. Simonsz, H. Stroink, A.P. Oranje, D.J. Halley, A. de Goede-Bolder, M.F. Niermeijer, S.M.de Muinck Keizer-Schrama, Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 100(4), 667–670 (1997).

    CAS  PubMed  Google Scholar 

  19. A.R. Shepard, W. Zhang, N.L. Eberhardt, Two CGTCA motifs and a GHF1/Pit1 binding site mediate cAMP-dependent protein kinase a regulation of human growth hormone gene expression in rat anterior pituitary GC cells. J. Biol. Chem. 269(3), 1804–1814 (1994)

    CAS  PubMed  Google Scholar 

  20. B. Dasgupta, L.L. Dugan, D.H. Gutmann, The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 23(26), 8949–8954 (2003)

    CAS  PubMed  PubMed Central  Google Scholar 

  21. E.H. Burrows, Bone changes in orbital neurofibromatosis. Br. J. Radiol. 36, 549–561 (1963)

    CAS  PubMed  Google Scholar 

  22. S.K. Gupta, H.V. Nema, P.L. Bhatia, K. Sasibabu, R. Kesharwani, The radiological features of craniofacial neurofibromatosis. Clin. Radiol. 30(5), 553–557 (1979)

    CAS  PubMed  Google Scholar 

  23. R.L. Agrawal, S. Bhargava, A.H. Samma, A.K. Kothari, H.K. Bedi, R.L. Shrimali, Empty sella syndrome with neurofibromatosis. Indian J. Ophthalmol. 24(4), 38–40 (1977)

    CAS  PubMed  Google Scholar 

  24. D. Miljic, S. Pekic, V. Popovic, Empty sella. In Endotext [Internet], eds by K.R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J.E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D.L. Trence, A. Vinik, D.P. Wilson (MDText.com, Inc, South Dartmouth, MA, 2018)

  25. L. De Marinis, S. Bonadonna, A. Bianchi, G. Maira, A. Giustina, Primary empty sella. J. Clin. Endocrinol. Metab. 90(9), 5471–5477 (2005)

    PubMed  Google Scholar 

  26. S. Chiloiro, A. Giampietro, A. Bianchi, T. Tartaglione, A. Capobianco, C. Anile, L. De Marinis, Diagnosis of endocrine disease: primary empty sella: a comprehensive review. Eur. J. Endocrinol. 177(6), R275–R285 (2017)

    CAS  PubMed  Google Scholar 

  27. A.M. Lenz, A.W. Root, Empty sella syndrome. Pediatr. Endocrinol. Rev. 9(4), 710–715 (2012)

    PubMed  Google Scholar 

  28. D. Rath, R.K. Sahoo, J. Choudhury, D.K. Dash, A. Mohapatra, Empty sella syndrome in a male child with failure to thrive. J. Pediatr. Neurosci. 10(1), 45–47 (2015)

    PubMed  PubMed Central  Google Scholar 

  29. R.E. Ferner, D.H. Gutmann, Neurofibromatosis type 1 (NF1): diagnosis and management. Handb. Clin. Neurol. 115, 939–955 (2013)

    PubMed  Google Scholar 

  30. P. Julayanont, A. Karukote, D. Ruthirago, D. Panikkath, R. Panikkath, Idiopathic intracranial hypertension: ongoing clinical challenges and future prospects. J. Pain. Res. 9, 87–99 (2016)

    CAS  PubMed  PubMed Central  Google Scholar 

  31. A.L. Gilbert, G. Heidary, Update on the evaluation of pediatric idiopathic intracranial hypertension. Curr. Opin. Ophthalmol. 27(6), 493–497 (2016)

    PubMed  Google Scholar 

  32. B. Shofty, L. Ben-Sira, S. Constantini, S. Freedman, A. Kesler, Optic nerve sheath diameter on MR imaging: establishment of norms and comparison of pediatric patients with idiopathic intracranial hypertension with healthy controls. AJNR Am. J. Neuroradiol. 33(2), 366–369 (2012)

    CAS  PubMed  Google Scholar 

  33. T. Mushtaq, F. Shakur, J.K. Wales, N.P. Wright, Reliability of the low dose synacthen test in children undergoing pituitary function testing. J. Pediatr. Endocrinol. Metab. 21(12), 1129–1132 (2008)

    CAS  PubMed  Google Scholar 

  34. M.C. Raux Demay, J.P. Magny, N. Idrès, A. Grimfeld, Y. Le Bouc, Use of the low-dose corticotropin stimulation test for the monitoring of children with asthma treated with inhaled corticosteroids. Horm. Res. 66(2), 51–60 (2006)

    CAS  PubMed  Google Scholar 

  35. L.M. Mongioì, R.A. Condorelli, F. Barbagallo, R. Cannarella, S. La Vignera, A.E. Calogero, Accuracy of the low-dose ACTH stimulation test for adrenal insufficiency diagnosis: a re-assessment of the cut-off value. J. Clin. Med. 8(6), pii: E806 (2019)

    Google Scholar 

  36. M. Wade, S. Baid, K. Calis, H. Raff, N. Sinaii, L. Nieman, Technical details influence the diagnostic accuracy of the 1 microg ACTH stimulation test. Eur. J. Endocrinol. 162(1), 109–113 (2010)

    CAS  PubMed  Google Scholar 

  37. A. Ciresi, S. Radellini, E. Vigneri, V. Guarnotta, J. Bianco, M.G. Mineo, C. Giordano, Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency. J. Endocrinol. Invest. 41(3), 333–342 (2018)

    CAS  PubMed  Google Scholar 

  38. C. Giavoli, R. Libé, S. Corbetta, E. Ferrante, A. Lania, M. Arosio, A. Spada, P. Beck-Peccoz, Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 89(11), 5397–5401 (2004)

    CAS  PubMed  Google Scholar 

  39. C. Giavoli, Unmasking other pituitary deficits during growth hormone replacement therapy. Ann. Endocrinol. 68(4), 237–240 (2007)

    CAS  Google Scholar 

  40. M. Tschöp, H. Lahner, H. Feldmeier, H. Grasberger, K.M. Morrison, O.E. Janssen, A.F. Attanasio, C.J. Strasburger, Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults. Eur. J. Endocrinol. 143(6), 769–773 (2000)

    PubMed  Google Scholar 

  41. L. De Paepe, R. Abs, J. Verlooy, A. Clemens, R.M. Smets, P. Louis, J.J. Martin, Benign intracranial hypertension as a cause of transient partial pituitary deficiency. J. Neurol. Sci. 114(2), 152–155 (1993)

    PubMed  Google Scholar 

  42. M.T. Zagardo, W.S. Cail, S.E. Kelman, M.I. Rothman, Reversible empty sella in idiopathic intracranial hypertension: an indicator of successful therapy? AJNR Am. J. Neuroradiol. 17(10), 1953–1956 (1996)

    CAS  PubMed  Google Scholar 

  43. V. Triggiani, V.A. Giagulli, M. Moschetta, E. Guastamacchia, An unusual case of reversible empty sella. Endocr. Metab. Immune Disord. Drug Targets. 16(2), 154–156 (2016)

    CAS  PubMed  Google Scholar 

  44. A. Giustina, G. Aimaretti, M. Bondanelli, F. Buzi, S. Cannavò, S. Cirillo, A. Colao, L. De Marinis, D. Ferone, M. Gasperi, S. Grottoli, T. Porcelli, E. Ghigo, E. degli Uberti, Primary empty sella: why and when to investigate hypothalamic-pituitary function. J. Endocrinol. Invest. 33(5), 343–346 (2010)

    CAS  PubMed  Google Scholar 

  45. R.E. Ferner, S.M. Huson, N. Thomas, C. Moss, H. Willshaw, D.G. Evans, M. Upadhyaya, R. Towers, M. Gleeson, C. Steiger, A. Kirby, Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44(2), 81–88 (2007)

    CAS  PubMed  Google Scholar 

  46. K.S. Cunha, E.P. Barboza, E.C. Fonseca, Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics 63(1), 39–42 (2008)

    PubMed  PubMed Central  Google Scholar 

  47. U. Dagalakis, M. Lodish, E. Dombi, N. Sinaii, J. Sabo, A. Baldwin, S.M. Steinberg, C.A. Stratakis, B.C. Widemann, Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J. Pediatr. 164(3), 620–624 (2014)

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece

    Eleni Magdalini Kyritsi & Christina Kanaka-Gantenbein

  2. Department of Neuroradiology, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece

    Maria Hasiotou

Authors
  1. Eleni Magdalini Kyritsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Hasiotou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christina Kanaka-Gantenbein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eleni Magdalini Kyritsi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the Ethics Committee of “Aghia Sophia” Children’s Hospital and all procedures performed were in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient’s parents before including the results of his investigations in this case report.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kyritsi, E.M., Hasiotou, M. & Kanaka-Gantenbein, C. Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1. Endocrine 69, 377–385 (2020). https://doi.org/10.1007/s12020-020-02351-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-020-02351-z

Keywords

Search

Navigation